Table 3.

Chronic effects that developed from anti–PD-1 therapy.

	Melanoma (n = 135)	RCC (n = 44)	NSCLC (n = 38)	Total (n = 217)
Adrenal insufficiency	6 (4.44%)	0	1 (2.63%)	7 (3.23%)
Arthritis/arthralgias	6 (4.44%)	1 (2.27%)	0	7 (3.23%)
Dermatitis	2 (1.48%)	0	0	2 (0.92%)
Diabetes	0	2 (4.54%)	0	2 (0.80%)
Dysphagia	1 (0.74%)	0	0	1 (0.46%)
Hypothyroidism	12 (9.45%)	6 (13.64%)	4 (10.52%)	22 (10.14%)
Neuropathy	4 (2.96%)	1 (2.27%)	1 (2.63%)	6 (2.76%)
Pneumonitis	3 (2.22%)	1 (2.27%)	0	4 (1.84%)

anti–PD-1, antibodies to programmed death-1 receptor.